Intensive Blood Glucose Control and Vascular Outcomes in …
2008年6月12日 · The ADVANCE trial is a factorial randomized, controlled trial conducted at 215 collaborating centers in 20 countries from Asia, Australasia, Europe, and North America (see the...
A Summary of the ADVANCE Trial - Diabetes Care
2009年11月1日 · The ADVANCE study has answered a number of important questions regarding glycemic control in patients with type 2 diabetes. It has clearly demonstrated that it is possible to achieve tight levels of glycemic control safely using conventional agents.
The ADVANCE Trial : results, clinical implications and perspectives
2008年3月18日 · The ADVANCE Trial is the largest-ever study aimed at investigating the effects of a treatment based on the fixed combination of an ACE-inhibitor (perindopril, 2mg) and a diuretic agent (indapamide, 0.625mg) on macrovascular and microvascular complications and deaths.
What did the ACCORD, ADVANCE, and VA Diabetes trials show?—
2009年1月1日 · The ADVANCE study randomized 11,140 participants at sites in Europe, Australia/New Zealand, Canada, and Asia to a strategy of intensive glycemic control (with primary therapy being the sulfonylurea gliclizide and additional medications as needed to achieve a target A1C of ≤6.5%) or to standard therapy (in which any medication but gliclizide ...
Effects of Intensive Glucose Lowering in Type 2 Diabetes
2008年6月12日 · We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular...
Follow-up of Blood-Pressure Lowering and Glucose Control in …
2014年10月9日 · In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced...
Institute for Advanced Study
The Institute for Advanced Study is one of the world’s foremost centers for theoretical research and intellectual inquiry. Located in Princeton, NJ, IAS is dedicated to independent study across the sciences and humanities.
The ADVANCE Study: Working to change blood donor eligibility
2022年8月10日 · The ADVANCE Study is a first step in providing data that will help the FDA determine if a donor history questionnaire based on individual risk would be as effective as the current time-based deferral, in reducing the risk of HIV in the blood supply.
Rationale and design of the ADVANCE study: a randomised trial …
The primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. Secondary outcomes include cause-specific cardiovascular end-points in …
ADVANCE Study Results Support Individual Donor Assessment
2023年8月31日 · Among sexually active men who have sex with men (MSM), many are at a lower risk for HIV infection and, therefore, should be considered eligible blood donors, according to highly anticipated results from the ADVANCE Study, published this week in Transfusion.